AIM: To assess the utility of an autologous CD34(+) and CD133(+) stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases. METHODS:One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group. RESULTS: Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted. CONCLUSION: Our data showed that a CD34(+) and CD133(+) stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
RCT Entities:
AIM: To assess the utility of an autologous CD34(+) and CD133(+) stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases. METHODS: One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group. RESULTS: Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted. CONCLUSION: Our data showed that a CD34(+) and CD133(+) stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
Authors: T X Fan; H Hisha; T N Jin; C Z Yu; Z X Lian; S B Guo; Y Z Cui; B Feng; G X Yang; Q Li; S Ikehara Journal: Stem Cells Date: 2001 Impact factor: 6.277
Authors: B E Petersen; W C Bowen; K D Patrene; W M Mars; A K Sullivan; N Murase; S S Boggs; J S Greenberger; J P Goff Journal: Science Date: 1999-05-14 Impact factor: 47.728
Authors: G Ferrari; G Cusella-De Angelis; M Coletta; E Paolucci; A Stornaiuolo; G Cossu; F Mavilio Journal: Science Date: 1998-03-06 Impact factor: 47.728
Authors: Christopher Booth; Tom Soker; Pedro Baptista; Christina L Ross; Shay Soker; Umar Farooq; Robert J Stratta; Giuseppe Orlando Journal: World J Gastroenterol Date: 2012-12-21 Impact factor: 5.742
Authors: Maria Giovanna Francipane; Melchiorre Cervello; Giovanni Battista Vizzini; Giada Pietrosi; Giuseppe Montalto Journal: Cell Med Date: 2011-06-01